FELLOW OPTIONAL
Isolated anti-HBc: do not force one interpretation
| Possibility | Clues | Reasonable next step |
| Remote resolved infection with waned anti-HBs | Prior risk, birth in an endemic region, old positive results | Document reactivation risk. HBV DNA before significant immunosuppression. |
| False-positive anti-HBc | Low pretest probability, no risk history, inconsistent repeat result | Repeat anti-HBc using the same assay to confirm a low-risk isolated result, as CDC recommends; obtain a new specimen and consult the laboratory if discordance persists. Vaccinate if susceptible. |
| Window-period acute HBV | Recent exposure, abrupt hepatitis, IgM anti-HBc positive | Repeat HBsAg/anti-HBs, obtain HBV DNA, and follow ALT/INR. |
| Occult HBV | HBsAg negative with detectable HBV DNA, especially during immunosuppression or unexplained hepatitis | Confirm HBV DNA and manage according to clinical setting and reactivation risk. |
A vaccine challenge is not a definitive diagnostic test for isolated anti-HBc. An anamnestic response can support prior immunity, but a response does not erase documented anti-HBc or remove future reactivation risk.
Discordant or indeterminate HBV findings
- New weak HBsAg positivity after vaccination: repeat after the period of possible transient antigenemia and obtain total anti-HBc/HBV DNA if current infection remains plausible.
- HBsAg and anti-HBs both positive: confirm results and obtain HBV DNA. Consider assay interference or passive antibody. Subtype-mismatched antibodies and surface-gene variants are reported explanations for coexistence; serology alone cannot identify the mechanism.
- IgM anti-HBc positive in known chronic HBV: assess for flare/reactivation. Do not label acute infection without timing, prior serology, HBV DNA trajectory, and clinical context.
- ALT high with HBV DNA <2,000: evaluate steatotic liver disease, alcohol, medications, HCV/HDV, autoimmune hepatitis, ischemia, and other causes. Continue serial HBV assessment because phase transition remains possible.
- HBV DNA high with unexpectedly negative HBsAg: repeat both assays and consider occult infection or an HBsAg escape variant.
Immunosuppression: where mistakes occur
- Ordering only HBsAg misses resolved infection and leaves patients with prior HBV unrecognized before rituximab or CAR-T therapy.
- Using anti-HBs positivity as permission to skip prophylaxis with B-cell depletion is incorrect.
- “Monitor liver enzymes” is not an adequate preemptive plan. HBV DNA must be included every 1–3 months, and the ordering clinician must own the results.
- Stopping prophylaxis when chemotherapy ends ignores delayed reactivation, especially after B-cell depletion, CAR-T therapy, or transplantation.
- New immunotherapies should be checked against current guidance. Checkpoint inhibitors can also cause immune-mediated hepatitis, so ALT elevation requires evaluation for both drug toxicity and HBV reactivation.
Stopping chronic HBV therapy
For HBeAg-negative adults, the 2025 guidance conditionally favors nucleos(t)ide therapy until HBsAg loss. Selected withdrawal is a specialist shared decision with very-low-certainty evidence. The proposed eligibility criteria exclude advanced fibrosis/cirrhosis, previous decompensation, HCC, extrahepatic HBV disease, HIV, and HDV. Other prerequisites include sustained undetectable HBV DNA, quantitative HBsAg <100 IU/mL, and dependable follow-up; if initially HBeAg positive, HBeAg loss with anti-HBe positivity must have persisted for at least 1 year. The guideline text and its algorithm differ on a minimum of 2 versus 3 years of suppression, and the evidence question also required at least 3 years of nucleos(t)ide therapy. That inconsistency prevents using the shortest interval as an automatic stopping rule.
The withdrawal monitoring schedule above is part of this specialist pathway. The guideline text calls for immediate restart if HBV DNA is ≥10,000 IU/mL regardless of ALT, ALT is ≥5 times ULN regardless of DNA, bilirubin is >2.5 mg/dL, or hepatic decompensation develops. Restart may also be appropriate for ordinary treatment indications, extrahepatic disease, or patient preference.
October 2026 HBV update: bepirovirsen
FDA approved bepirovirsen (Hibsago) on October 20, 2026, after the AASLD guideline. It is added to nucleos(t)ide therapy in selected noncirrhotic adults treated for at least 6 months, with suppressed HBV DNA and HBsAg ≤3,000 IU/mL by an FDA-authorized test. Specialist selection and dependable laboratory access are essential.
The FDA label separates a maximum 24-week bepirovirsen course from the subsequent period of nucleos(t)ide therapy, which continues for at least 24 additional weeks. Completion of injections alone does not justify stopping the background antiviral. The selected withdrawal population is HBeAg negative, with HBV DNA below quantification (<20 IU/mL), undetectable HBsAg at the labeled assay sensitivity (limit of detection 0.05 IU/mL), ALT ≤2 times ULN, and no continuing need for nucleos(t)ide therapy to treat HIV. Close laboratory and clinical follow-up continues for at least 1 year after nucleos(t)ide cessation. HBV-directed withdrawal must not interrupt effective HIV treatment.
Contraindications include acute hepatic impairment, cirrhosis, and baseline platelets <100 × 109/L. Boxed warnings concern hepatic flares and thrombocytopenia. Baseline assessment includes HBV markers, hepatic tests, platelets, eGFR, and urine albumin-to-creatinine ratio. Minimum on-treatment monitoring is platelets weekly, ALT/bilirubin weekly through week 12 then every other week, and eGFR every other week through week 24. Abnormal results change testing frequency and can require interruption or permanent discontinuation under the label.
No dose adjustment is recommended for mild renal impairment; safety data are insufficient in moderate/severe renal impairment, pregnancy, and HCV coinfection. HDV coinfection and concomitant peginterferon are not recommended. Review anticoagulants, antiplatelets, platelet-lowering drugs, and nephrotoxic drugs. Hold treatment and obtain platelets promptly for new bleeding; unexplained immune-mediated toxicity requires permanent discontinuation. This is a distinct labeled pathway, not permission for routine antiviral withdrawal.
HCV situations outside simplified treatment
| Situation | Why it changes management |
| Prior DAA exposure | Regimen history, genotype, cirrhosis, resistance context, and prior failure determine retreatment. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is a common salvage backbone, but it contains a protease inhibitor and is not for decompensated cirrhosis. |
| Decompensated cirrhosis | NS3 protease inhibitors are excluded. In patients without prior sofosbuvir/NS5A treatment failure, sofosbuvir/velpatasvir is paired with ribavirin for a 12-week course when ribavirin is suitable, or used for 24 weeks without it when ribavirin is unsuitable. The ribavirin-free 24-week course is guideline-supported off-label use. Prior sofosbuvir/NS5A failure changes the pathway, generally to 24 weeks with ribavirin under specialist care, based on lower-certainty evidence. |
| Ribavirin eligibility | Assess renal function, hemoglobin, cardiac disease, pregnancy risk, hemoglobinopathies, and interacting drugs. It is contraindicated during pregnancy, when a male patient’s partner is pregnant, with hemoglobinopathies, and with didanosine. Avoid it with significant or unstable cardiac disease. Use product-specific renal dosing and pregnancy-prevention instructions; monitor hemoglobin before treatment, at weeks 2 and 4, and thereafter as indicated. Child-Pugh C patients generally start at a reduced ribavirin dose in the specialist pathway. |
| HBsAg positive | Concurrent HBV requires a separate treatment or reactivation-prevention plan. |
| Pregnancy | Routine DAA treatment during pregnancy is not yet a standard simplified pathway; individualize with maternal-fetal medicine and hepatology/ID. |
| Solid-organ transplant, HCC, or severe renal complexity | Drug interactions, graft status, cancer timing, and regimen-specific evidence require specialist selection. |
| Persistent ALT elevation after SVR | SVR does not explain ongoing hepatitis. Evaluate alcohol, MASLD, HBV, autoimmune disease, iron overload, medications, and other causes. |